-
FDA approves subcutaneous formulation of Orencia
PRINCETON, N.J. — The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for injection under the skin to treat rheumatoid arthritis, Bristol said Friday.
The New York-based drug maker said the approval of Orencia (abatacept) for subcutaneous injection in patients with moderate to severe RA made it the first biotech drug for RA available in self-injectable and intravenous infusion formulations.
-
Federal court upholds Lilly patent
INDIANAPOLIS — A federal court has upheld Eli Lilly's patent covering a drug used to treat attention deficit hyperactivity disorder, Lilly said Friday.
Lilly said the U.S. Court of Appeals for the Federal Circuit overturned a ruling by the U.S. District Court for the District of New Jersey that had invalidated Lilly's patent for Strattera (atomoxetine) in a patent infringement case that Lilly had filed against generic drug maker Actavis, when the latter sought regulatory approval for a generic version of Strattera.